Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status. Among patients with advanced urothelial carcinoma, ...

Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 ...

As with other drugs, Bavencio (avelumab) can cause side effects, such as fatigue or muscle and bone pain. If you’re not able to tolerate side effects of Bavencio, talk with your doctor or ...

Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only cancer ...

Maintenance Bavencio with Inlyta interruption is feasible in mRCC, showing promising PFS and OS rates at 31.7 months follow-up. Patients interrupting Inlyta at week 36 had a 24-month PFS rate of 58% ...